BENOIT LALEU

Dr. BENOIT LALEU

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2016 in International Journal for Parasitology: Drugs and Drug Resistance
Verified
Journal Article
Open access
SPSarah Preston
Sarah Preston
YJYaqing Jiao
Yaqing Jiao
Abdul JabbarAbdul Jabbar
Abdul Jabbar
SMSean L. McGee
Sean L. McGee
BLBENOIT LALEU
BENOIT LALEU
RGRobin Gasser
Robin Gasser
There is a substantial need to develop new medicines against parasitic diseases via public-private partnerships. Based on high throughput phenotypic screens of largely protozoal pathogens and bacteria, the Medicines for Malaria Venture (MMV) has recently assembled an open-access 'Pathogen Box' containing 400 well-curated chemical compounds. In the present study, we tested these compounds for activity against parasitic stages of the nematode Haemonchus contortus (barber's pole worm). In an optimised, whole-organism screening assay, using exsheathed third-stage (xL3) and fourth-stage (L4) larvae, we measured the inhibition of larval motility, growth and development of H. contortus. We also studied the effect of the 'hit' compound on mitochondrial function by measuring oxygen consumption. Among the 400 Pathogen Box compounds, we identified one chemical, called tolfenpyrad (compound identification code: MMV688934) that reproducibly inhibits xL3 motility as well as L4 motility, growth and development, with IC50 values ranging between 0.02 and 3 μM. An assessment of mitochondrial function showed that xL3s treated with tolfenpyrad consumed significantly less oxygen than untreated xL3s, which was consistent with specific inhibition of complex I of the respiratory electron transport chain in arthropods. Given that tolfenpyrad was developed as a pesticide and has already been tested for absorption, distribution, excretion, biotransformation, toxicity and metabolism, it shows considerable promise for hit-to-lead optimisation and/or repurposing for use against H. contortus and other parasitic nematodes. Future work should assess its activity against hookworms and other pathogens that cause neglected tropical diseases.

27 May 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
KKKrittikorn Kümpornsin
Krittikorn Kümpornsin
TKTheerarat Kochakarn
Theerarat Kochakarn
TYTomas Yeo
Tomas Yeo
JOJohn Okombo
John Okombo
MLMadeline R. Luth
Madeline R. Luth
MLMarcus C. S. Lee
Marcus C. S. Lee
In vitro evolution of drug resistance is a powerful approach for identifying antimalarial targets, however, key obstacles to eliciting resistance are the parasite inoculum size and mutation rate. Here we sought to increase parasite genetic diversity to potentiate resistance selections by editing catalytic residues of Plasmodium falciparum DNA polymerase δ. Mutation accumulation assays reveal a ~5–8 fold elevation in the mutation rate, with an increase of 13–28 fold in drug-pressured lines. Upon challenge with the spiroindolone PfATP4-inhibitor KAE609, high-level resistance is obtained more rapidly and at lower inocula than wild-type parasites. Selections also yield mutants with resistance to an “irresistible” compound, MMV665794 that failed to yield resistance with other strains. We validate mutations in a previously uncharacterised gene, PF3D7_1359900, which we term quinoxaline resistance protein (QRP1), as causal for resistance to MMV665794 and a panel of quinoxaline analogues. The increased genetic repertoire available to this “mutator” parasite can be leveraged to drive P. falciparum resistome discovery.

16 March 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
SBSelina Bopp
Selina Bopp
Charisse Flerida PasajeCharisse Flerida Pasaje
Charisse Flerida Pasaje
RSRobert L. Summers
Robert L. Summers
PMPamela Magistrado-Coxen
Pamela Magistrado-Coxen
KSKyra A. Schindler
Kyra A. Schindler
DWDyann F. Wirth
Dyann F. Wirth
Identifying how small molecules act to kill malaria parasites can lead to new “chemically validated” targets. By pressuring Plasmodium falciparum asexual blood stage parasites with three novel structurally-unrelated antimalarial compounds (MMV665924, MMV019719 and MMV897615), and performing whole-genome sequence analysis on resistant parasite lines, we identify multiple mutations in the P. falciparum acyl-CoA synthetase (ACS) genes PfACS10 (PF3D7_0525100, M300I, A268D/V, F427L) and PfACS11 (PF3D7_1238800, F387V, D648Y, and E668K). Allelic replacement and thermal proteome profiling validates PfACS10 as a target of these compounds. We demonstrate that this protein is essential for parasite growth by conditional knockdown and observe increased compound susceptibility upon reduced expression. Inhibition of PfACS10 leads to a reduction in triacylglycerols and a buildup of its lipid precursors, providing key insights into its function. Analysis of the PfACS11 gene and its mutations point to a role in mediating resistance via decreased protein stability.

26 August 2021 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
BLBENOIT LALEU
BENOIT LALEU
YAYuichiro Akao
Yuichiro Akao
AOAtsuko Ochida
Atsuko Ochida
SDSandra Duffy
Sandra Duffy
LLLeonardo Lucantoni
Leonardo Lucantoni
MKMasahiro Kamaura
Masahiro Kamaura
A phenotypic high-throughput screen allowed discovery of quinazolinone-2-carboxamide derivatives as a novel antimalarial scaffold. Structure–activity relationship studies led to identification of a potent inhibitor 19f, 95-fold more potent than the original hit compound, active against laboratory-resistant strains of malaria. Profiling of 19f suggested a fast in vitro killing profile. In vivo activity in a murine model of human malaria in a dose-dependent manner constitutes a concomitant benefit.

10 October 2022 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
MLMartin A. Lowe
Martin A. Lowe
ACAlvaro Cardenas
Alvaro Cardenas
JVJean-Pierre Valentin
Jean-Pierre Valentin
ZZZhaoning Zhu
Zhaoning Zhu
JAJan Abendroth
Jan Abendroth
THTeresa de Haro
Teresa de Haro
Plasmepsin X (PMX) is an essential aspartyl protease controlling malaria parasite egress and invasion of erythrocytes, development of functional liver merozoites (prophylactic activity), and blocking transmission to mosquitoes, making it a potential multistage drug target. We report the optimization of an aspartyl protease binding scaffold and the discovery of potent, orally active PMX inhibitors with in vivo antimalarial efficacy. Incorporation of safety evaluation early in the characterization of PMX inhibitors precluded compounds with a long human half-life (t1/2) to be developed. Optimization focused on improving the off-target safety profile led to the identification of UCB7362 that had an improved in vitro and in vivo safety profile but a shorter predicted human t1/2. UCB7362 is estimated to achieve 9 log 10 unit reduction in asexual blood-stage parasites with once-daily dosing of 50 mg for 7 days. This work demonstrates the potential to deliver PMX inhibitors with in vivo efficacy to treat malaria.

31 May 2017 in Parasites & Vectors
Verified
Journal Article
Open access
PDF file
YJYaqing Jiao
Yaqing Jiao
SPSarah Preston
Sarah Preston
HSHongjian Song
Hongjian Song
Abdul JabbarAbdul Jabbar
Abdul Jabbar
YLYuxiu Liu
Yuxiu Liu
RGRobin Gasser
Robin Gasser
In this study, we tested five series of pyrazole-5-carboxamide compounds (n = 55) for activity against parasitic stages of the nematode Haemonchus contortus (barber’s pole worm), one of the most pathogenic parasites of ruminants. In an optimised, whole-organism screening assay, using exsheathed third-stage (xL3) and fourth-stage (L4) larvae, we measured the inhibition of larval motility and development of H. contortus. Amongst the 55 compounds, we identified two compounds (designated a-15 and a-17) that reproducibly inhibit xL3 motility as well as L4 motility and development, with IC50 values ranging between ~3.4 and 55.6 μM. We studied the effect of these two ‘hit’ compounds on mitochondrial function by measuring oxygen consumption. This assessment showed that xL3s exposed to each of these compounds consumed significantly less oxygen and had less mitochondrial activity than untreated xL3s, which was consistent with specific inhibition of complex I of the respiratory electron transport chain in arthropods. The present findings provide a sound basis for future work, aimed at identifying the targets of compounds a-15 and a-17 and establishing the modes of action of these chemicals in H. contortus.